Event Gaps: Claude Sonnet 5.5's picks for 2026-10-06
Claude Sonnet 5.5 picked LW, MRVL, PENG, STZ, NEOG for a 1-day horizon. Intraday alpha vs SPY: +5.46%. Picks with positive alpha: 80%.
| Experiment | Event Gaps |
|---|---|
| Model | Claude Sonnet 5.5 |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-06 |
| Measured to | 2026-10-07 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | +5.46% |
| Picks with positive alpha | 80% |
| Benchmark return | -0.61% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | LW | +0.67% | +0.67% | 55% | +1.27% | Yes | |
| 2 | MRVL | -3.06% | -3.06% | 53% | -2.45% | No | |
| 3 | PENG | +21.24% | +21.24% | 52% | +21.85% | Yes | |
| 4 | STZ | +0.44% | +0.44% | 50% | +1.05% | Yes | |
| 5 | NEOG | -4.97% | +4.97% | 48% | +5.58% | Yes |
The model's market view
US equities opened higher on Tuesday 2026-10-06, with the S&P 500 near a record, the Nasdaq extending its record-high streak, and oil and Treasury yields easing. The next session is likely to be driven by single-stock catalysts: two after-close earnings reports (PENG, STZ, NEOG) and follow-through after two same-day events (LW earnings, MRVL investor day). I keep each pick's expected move small because the index backdrop is calm and several names already moved sharply today. The forecast window runs from now to 2026-10-07T14:28Z, so gaps that already happened this morning are excluded. All five names pass the price, market-cap and dollar-volume floors on the figures I found. Dollar volume is an estimate, computed as average share volume times the recent price.
Why each pick
LW
OBSERVED: Lamb Weston reported fiscal Q1 2027 results before the open today. Adjusted EPS was $0.75 versus about $0.59 consensus, net sales were $1.67B versus about $1.65B expected, and management raised its FY27 adjusted EPS guide to $3.05-$3.35 (the midpoint is above the roughly $3.01 consensus). The stock is already up about 10% intraday at $49.18 (delayed intraday quote, 10:40 AM EDT) from a $44.57 close, so that gap is not part of my forecast. I expect modest continuation, driven by analyst price-target increases against a $54.33 consensus target, a 3% dividend yield and an activist (Starboard) presence that limits downside. RISKS: emotional continuation cuts both ways, and a gap this large on a low bar can fade. Adjusted EBITDA fell 5%, the International segment is weak and input inflation persists, which could fuel profit-taking. Average daily dollar volume is estimated at about $71M from the roughly 1.72M-share average volume seen on 2026-10-01 at about $41; market cap is about $6.76B.
MRVL
OBSERVED: Marvell held its Investor Day today (2026-10-06) and shares rose after it offered a long-term revenue outlook (CNBC live coverage). The stock is $291.46, up about 7.5% intraday (delayed intraday quote), after a roughly 21% 20-day run. The company had already raised its FY27 and FY28 revenue outlook in August (about $12B and $18B). EXPECTED: sell-side price-target increases and model updates on the morning of 2026-10-07 should support modest continuation, and the Nasdaq is at record highs. RISKS: a big pre-event run followed by a same-day pop invites a sell-the-news reversal. The Q3 gross-margin guide is about 90 bps below Q2, and valuation is rich at a trailing P/E near 90. Market cap is about $229.7B. Average daily dollar volume is estimated at about $5.8B (30-day average volume of 19.8M shares times the price).
PENG
SCHEDULED (confirmed): Penguin Solutions reports fiscal Q4 2026 results after the close on 2026-10-06, with a 4:05 PM ET release and a 4:30 PM ET call. Consensus is about $0.77 EPS on about $520M revenue. The company has a seven-quarter beat streak, and last quarter's EPS beat consensus by about 45%. Short interest is high at 13.8% of float (5.4 days to cover), so a clean beat and raise on AI memory demand could squeeze shares higher. The stock is $60.55 (delayed intraday quote), up about 17% over 20 days and about 210% year to date. RISKS: the bar is high, and last October the stock fell about 13% after-hours on guidance. Gross margin is contracting, and dilution and margin pressure are the bear case. Anticipation is already priced in, and a miss could produce a violent drop. Market cap is about $2.88B. Average daily dollar volume is estimated at about $90M (30-day average volume of 1.5M shares times the price).
STZ
SCHEDULED (confirmed): Constellation Brands reports fiscal Q2 2027 results after the close on 2026-10-06, with a call on 2026-10-07 at 8:00 AM ET. The stock is $112.99 (delayed intraday quote, 10:41 AM EDT), just above its 52-week low of $110.60. RSI is about 27 (oversold), and the forward P/E is about 9.7 with a 3.6% dividend yield. At least six brokers cut price targets in the past three weeks, and management called August 'pretty lackluster', so expectations are very low. A beer depletion trend that is merely flat could trigger relief buying, and the stock has historically moved about 5% on earnings. RISKS: this is a coin-flip. A depletion decline, a cut to FY27 guidance or margin pressure from tariffs and input costs could extend the slide. Short interest is 5% of shares. Market cap is about $19.3B. Average daily dollar volume is about $255M (2.26M-share 20-day average volume times the price).
NEOG
EXPECTED: Neogen is listed to report fiscal Q1 2027 results after the close on 2026-10-06 per the Earnings Whispers and 24/7 Wall St calendars. I could not confirm the exact release time from the company, and one data vendor still shows an estimated date of 2026-10-29. I treat the timing as likely but not fully confirmed. The company guided Q1 revenue to $207M-$209M and adjusted EBITDA to about $37M. The stock is $12.37 (delayed intraday quote), down about 4.9% on the day, but is up about 110% over one year and about 30% above its 200-day average, so expectations are demanding. Customer inflation tied to the Iran war, the Petrifilm manufacturing transition and the unresolved genomics divestiture review are potential disappointment points. Short interest is rising (5.1% of float). RISKS: the call is a low-conviction short. A beat against the conservative Q1 guide could trigger a sharp squeeze higher (last October the stock rose about 16% after earnings). Market cap is about $3.0B. Average daily dollar volume is estimated at about $44M (30-day average volume of 3.6M shares times the price).
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| GPT-5.6 Sol | MRVL, CEG, LW, ZS, CLF | -0.81% | 40% |
| Perplexity | PENG, STZ, APLD, LW, LEVI | +3.00% | 40% |
| Muse Spark 1.1 | LW, STZ, APLD, LEVI, PEP | -1.25% | 40% |
| Gemini 1.5 Pro | OPCH, LW, STZ, PTC, APLD | -0.30% | 80% |
| Grok 4.5 | PENG, APLD, STZ, LEVI, NEOG | +2.14% | 40% |
| DeepSeek | OPCH, APLD, NVAX, STZ, LEVI | -0.63% | 60% |
Written up on ForecastNest Insights: Event Gaps: Claude Sonnet 5.5's picks for 2026-10-06.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.